ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1819

Predictors of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

Anna Gramling1, Kaleb Michaud2, Harlan Sayles3, Frederick Wolfe4 and Michelene Hearth-Holmes5, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 3Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4National Data Bank for Rheumatic Diseases, Wichita, KS, 5Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and vaccines

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are at high risk for serious infection, including those caused by Streptococcus pneumoniae. Administration of 23-valent polysaccharide pneumococcal vaccination (23-PPV) is recommended for patients with several co-morbidities and age >65 years. EULAR recommends 23-PPV for all patients with autoimmune inflammatory rheumatic diseases and the ACR recommends it for all patients with RA. Small observational studies suggest that administration of 23-PPV in RA patients is inadequate while none studied SLE. The purpose of our study is to determine rates and predictors of 23-PPV administration in US RA and SLE patients.

Methods: We surveyed patients across the US with RA, SLE, or osteoarthritis (OA) every 6 months from 2007 through 2011 about 23-PPV along with their demographic and health status. We identified characteristics within each diagnosis that predicted administration of 23-PPV in a subsequent 6-month period through the use of univariate logistic regression adjusted for sex and age > 65 years.  Significant predictors were combined in a multivariate logistic regression model and eliminated with backward stepwise selection until all remaining predictors were significant for an alpha of 0.05.  We also selected a subset of cases who had never received 23-PPV at baseline and used univariate Cox proportional hazards models controlling for diagnosis group to predict the timing of the first administration of 23-PPV.  Significant predictors were combined in a multivariate Cox proportional hazards model and eliminated with backward stepwise selection until all remaining predictors were significant for an alpha of 0.05.

Results:  A total of 15,954 patients participated in the study (11,952 RA, 1,773 SLE, and 2,229 OA). Among these groups 69.8%, 65.2%, and 67.8% of patients reported having ever received 23-PPV, respectively.  SLE patients who reported receiving 23-PPV in the subsequent 6 months were more likely to be over 65 (OR 1.64, p=0.01), taking prednisone (OR 1.38, p=0.01), and to have chronic lung disease (OR 1.68, p<0.01).   RA patients age > 65 (OR 1.70, p<0.01), male (OR 1.16, p=0.01), on biologic therapy (OR 1.18, p=0.03) or prednisone (OR 1.20, p<0.01), and suffering from chronic lung (OR 1.53, p<0.01) or heart disease (OR 1.20, p=0.03) were more likely to receive 23-PPV.  Age > 65 was the strongest predictor of 23-PPV use in OA patients (OR 2.06, p<0.01). Patients were more likely to receive their first 23-PPV if they were over 65 (HR=2.05, p<0.01), male (HR=1.2, p=0.01), taking a non-biological DMARD (HR=1.32, p<0.01), taking a biological DMARD (HR=1.31, p<0.01), had chronic lung disease (HR=1.33, p<0.01), or had a lower SF36 PCS score (HR=0.99, p<0.01).

Conclusion: Despite current EULAR and ACR recommendations nearly a third of RA and SLE patients have never received a pneumococcal vaccination in a large, contemporary US cohort. Age greater than 65 years and chronic lung disease were the strongest predictors of 23-PPV administration. This is the first study to report that use of immunosuppressive drugs other than prednisone was not associated with pneumococcal vaccination in SLE patients.


Disclosure:

A. Gramling,
None;

K. Michaud,
None;

H. Sayles,
None;

F. Wolfe,
None;

M. Hearth-Holmes,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-pneumococcal-vaccination-in-patients-with-rheumatoid-arthritis-and-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology